The Source for High Quality Small Molecule Kinase Inhibitors

SYNkinase is a primary producer of research-use-only biomedical reagents, for life science and drug discovery researchers at universities, research institutes and industry. SYNkinase was established in 2008 with an office in Australia, USA and Europe and research and development laboratories in Shanghai/China. The founders of the company have been involved in pharmaceutical drug discovery for three decades and include kinase biology scientists and expert medicinal and synthetic chemists.

SYNkinase's mission is to provide life science researchers with access to the world's most up-to-date library of kinase inhibitors and other small molecule inhibitors of important therapeutic proteins for drug discovery. SYNkinase offers a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK) as well as lipid kinases. There are more than 150 kinase targeted drugs in clinical trials or development at present. Twenty-four small molecule inhibitors have been FDA-approved including mTOR, BRaf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR, TGF-β, MAP kinase, cell cycle and epigenetic inhibitors. As a primary source manufacturer, SYNkinase maintains a fastidious focus on quality, ensuring that they can consistently supply the same high quality material, as well as being first in the market with the most important and cutting-edge compounds.

AdipoGen Life Sciences offersall SYNkinase Products on an exclusive and in some territories non-exclusive base. Please contact us if you request more information.

For Product Inquiries: info@adipogen.com

Newly Released

Alpelisib (SYN-1230) - Selective PI3Kα inhibitor with IC₅₀ of 5nM.

Selonsertib (free base) (SYN-1231) - Orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.

Olaparib (SYN-3043) - Selectively binds to and inhibits PARP (IC₅₀ of 1-5nM in cell-free assays), inhibiting PARP-mediated repair of single strand DNA breaks.

More Information
SYNKinase Inhibitor Product Flyer Including over 60 compounds unique to SYNkinase!		Download
Search AdipoGen for a complete Overview on all Products.